NAION & Vision Loss From Ozempic and Other GLP-1s

If you were diagnosed with NAION or experienced sudden vision loss after taking Ozempic, Wegovy, Mounjaro, or other GLP-1 medications, you may be eligible to file a lawsuit and recover compensation for your injury.  

Find out whether you qualify or start your claim today by calling Hissey, Mulderig & Friend toll-free at 1-866-806-8117 or by filling out the free case evaluation form on this page. 

What Is NAION?

Non-arteritic anterior ischemic optic neuropathy, or NAION, is a condition that occurs when blood flow to the optic nerve becomes reduced or blocked.  

The optic nerve carries visual signals from the eye to the brain, and it depends on a steady supply of oxygen and nutrients to function. When that supply is interrupted, the nerve tissue can quickly become damaged. 

Doctors sometimes describe NAION as an “eye stroke” because it tends to occur suddenly and without warning. Unlike eye conditions that develop slowly over months or years, NAION often appears overnight. Because the optic nerve does not regenerate, the resulting vision loss is frequently permanent. 

Symptoms of Ozempic-Related Vision Loss

Patients who develop NAION usually notice changes in one eye first, although the condition can eventually involve both eyes. Many people report that they first became aware of the problem upon waking in the morning. 

Common symptoms associated with NAION include:  

  • Sudden vision loss in one eye 
  • Blurred or dimmed vision 
  • Dark or missing areas within the field of vision, and  
  • Reduced or weakened color perception.  

NAION is typically painless, which can lead some patients to delay seeking care.  

Anyone who experiences a sudden change in vision should be evaluated by an ophthalmologist or neuro-ophthalmologist as quickly as possible, both to protect their health and to document what happened. 

Medical Evidence Linking GLP-1 Drugs to NAION

Concern about a possible connection between semaglutide medications and optic nerve injury grew after researchers began studying patients who developed vision problems while taking these drugs.  

A study published in JAMA Ophthalmology found that patients taking semaglutide, the active ingredient in Ozempic and Wegovy, were significantly more likely to be diagnosed with NAION than patients receiving other treatments. The increased risk was even more pronounced among overweight patients. 

The Growing GLP-1 Vision Loss Litigation

Patients who developed NAION after using Ozempic and similar medications have filed lawsuits alleging that the manufacturers failed to adequately warn them and their doctors about the risk of optic nerve damage.  

These claims have argued that the drug companies knew or should have known about the potential danger, that the warnings provided were insufficient, and that patients were never given the information they needed to make an informed decision before starting treatment. 

The NAION litigation has moved quickly. After dozens of cases were filed in state and federal courts, the federal judiciary consolidated the GLP-1 vision loss claims into a single multidistrict litigation in December 2025. Attorneys expect the number of vision loss claims to continue rising as more patients learn about the possible link between these drugs and NAION. 

Contact An Attorney to Start Your Claim

Our law firm, Hissey Mulderig & Friend, is currently investigating cases involving NAION and serious vision loss linked to Ozempic or other GLP-1 medications. 

If you or a loved one was diagnosed with NAION or suffered sudden vision loss after taking Ozempic, Wegovy, Mounjaro, or other GLP-1 drugs, you may qualify to file a lawsuit and pursue compensation for your injury.  

Find out whether you qualify or begin your claim today by contacting Hissey, Mulderig & Friend toll-free at 1-866-806-8117, or by filling out our free case evaluation form at the top of this page. 

Start Your Claim

Name(Required)